I read with keen interest, the argument put forward by Novartis in their letter to Business and Human Rights Resource Center in support of strengthened patent law as the ultimate safeguard required for pharmaceutical innovation to flourish. The caption of their paper rightly says ‘Why Novartis thinks improving patent will benefit patients and society’. But quite surprisingly throughout the entire length and breadth of their position paper, they failed to show how these ‘imaginary’ benefits will materialize for patients...